IL2 and autoimmune disease: A trial comparing the effect of low-dose IL-2 across 11 autoimmune diseases found an increase in both memory and naïve Treg subsets [106] It remains to be seen whether dosing and treatment regimen can influence the phenotype of expanded Tregs in vivo.